Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Incyte Corp (NQ: INCY )

65.24 -0.63 (-0.96%)
Streaming Delayed Price Updated: 2:05 PM EDT, Jul 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 436,970
Open 66.09
Bid (Size) 65.24 (2)
Ask (Size) 65.27 (4)
Prev. Close 65.87
Today's Range 64.30 - 66.16
52wk Range 50.27 - 67.36
Shares Outstanding 222,430,635
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Looking for growth without the hefty price tag? Consider NASDAQ:INCY.
INCYTE CORP (NASDAQ:INCY) is showing decent growth, but is still valued reasonably. 
Via Chartmill
NASDAQ:INCY is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
INCYTE CORP (NASDAQ:INCY), an undervalued stock with good fundamentals. 
Via Chartmill

Performance

YTD
-0.32%
-0.32%
1 Month
+3.20%
+3.20%
3 Month
+25.65%
+25.65%
6 Month
+6.08%
+6.08%
1 Year
+2.80%
+2.80%

More News

Read More
S&P 500 Hits Record Highs, Eyes 6th Straight Gain As Powell Keeps Bears At Bay; Tesla Targets 10th Consecutive Win, Bank Stocks Rally: What's Driving Markets Tuesday?
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Incyte to Report Second Quarter Financial Results
From Incyte
Via Business Wire
NASDAQ:INCY is not too expensive for the growth it is showing.
Via Chartmill
Analyst Expectations For Incyte's Future
Via Benzinga
Despite its growth, NASDAQ:INCY remains within the realm of affordability.
Via Chartmill
The 3 Most Undervalued Cathie Wood Stocks to Buy in July 2024
Via InvestorPlace
7 Cheap Biotech Stocks With Major Upside Potential
Via InvestorPlace
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
3 Highly Rated Biotech Stocks for Your July Buy List
Via InvestorPlace
9 Analysts Have This To Say About Incyte
Via Benzinga
This CrowdStrike Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Via Benzinga
Stocks Chop As Wall Street Unpacks Powell Comments
Via Talk Markets
Topics Economy
Exposures Interest Rates
7 Undervalued Biotech Stocks to Buy for Big-Time Returns
Via InvestorPlace
For those who appreciate value investing, NASDAQ:INCY is a compelling option with its solid fundamentals.
Via Chartmill
Nasdaq 100, S&P 500 Close At Record Highs As Tech Stocks Reclaim Dominance: Thursday's Gainers & Losers
Via Benzinga
Topics Stocks
Exposures US Equities
Incyte Announces Final Results of Tender Offer
From Incyte Corporation
Via Business Wire
Incyte Announces Preliminary Results of Tender Offer
From Incyte Corporation
Via Business Wire
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Incyte Completes Acquisition of Escient Pharmaceuticals
From Incyte
Via Business Wire
When you look at NASDAQ:INCY, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Via Chartmill
Hedge Funds Tweak Portfolios In Q1: Marvell, TD Synnex, AES Get More Love As Focus Shifts To AI
Via Benzinga
Incyte Expands Presence in Delaware through Acquisition of Two Downtown Wilmington Office Buildings
From Incyte
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.